Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type

Interventional

Phase

Not applicable

Age range

18 years - Not specified

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

35 Actual

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

To test the use of a continuous activity and heart rate tracker (Fitbit) and continuous glucose monitor (CGM) in monitoring daily exercise-related activities.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

• Men and women at least 18 years old
• Body mass index (BMI) 25 kg/m2
• Engage in less than 150 minutes of moderate-intensity PA per week in the past month
• Capable of participating in moderate-vigorous unsupervised exercise (as determined by the Physical Activity Readiness Questionnaire (PARQ) or a medical release from their physician)
• Self-reported ability to walk one block without pain or discomfort
• Have a smart phone with daily internet access that is compatible with the LibreLink app
• Ability to speak, read, and write in English
• For the cancer survivor cohort (participant accession number #21 and beyond), individuals must have been diagnosed with stage I-III breast or colorectal cancer and completed adjuvant therapy (i.e., chemo and/or radiation therapy).

Exclusion Criteria:

• Self-reported current diagnosis or history of type 1 diabetes or type 2 diabetes
• Self-reported use of oral antidiabetic agents (OADs)
• Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator)
• Current use of a continuous glucose monitor
• Fasting glucose \> 125 mg/dL
• Pregnancy
• Self-reported health issues that limit physical activity
• On dialysis
• Work overnight shifts
• Unwilling to use CGM
• Current participation in other wellness or weight loss-related program or intervention
• Currently on a low-carb diet
• Unable to receive REDCap survey through their mobile phones

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not randomized

Masking

No masking

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Study team and timeline

Lead sponsor

M.D. Anderson Cancer Center

Study start

May 24, 2018 Actual

Primary completion

Jan 31, 2027 Estimated

Study completion

Jan 31, 2027 Estimated

First posted

Nov 18, 2021 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts

No central contact is listed. Check the locations and the official record.